Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
Another Roche TIGIT disappointment
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Vor looks to answer the Car-T question
Can the company add a Car-T string to its stem cell transplant bow?
Make or break time for Caribou
The company’s matching strategy for CB-010 will soon be put to the test.
